Levonorgestrel, medroxyprogesterone and progesterone cause a concentration-dependent reduction in endometrial cancer (ishikawa) cell density, and high concentrations of progesterone and mifepristone act in synergy

Anticancer Research

Volumn 29, Issue 4, 2009, Pages 1047-1052

  Moe, Bjoørn T ^a   Vereide, Anne B ^a   Ørbo, Anne ^a   Leger, Ragnhild ^a   Sager, Georg ^a,b  

^a University Oftromsø   (Norway)

^b UNIVERSITY OF TROMSØ   (Norway)

Author keywords

Antiprogestins; Cancer; Growth; Ishikawa cells; Pharmacology; Progestins

Indexed keywords

ANTIGESTAGEN; GESTAGEN; LEVONORGESTREL; MEDROXYPROGESTERONE; MIFEPRISTONE; PROGESTERONE;

ARTICLE; CELL DENSITY; CONCENTRATION RESPONSE; DRUG EFFECT; DRUG POTENCY; DRUG POTENTIATION; ENDOMETRIUM CANCER; FEMALE; HUMAN; HUMAN CELL; IC 50; IN VITRO STUDY; PRIORITY JOURNAL;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CELL LINE, TUMOR; CONTRACEPTIVES, ORAL, SYNTHETIC; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG SYNERGISM; ENDOMETRIAL NEOPLASMS; FEMALE; HUMANS; LEVONORGESTREL; MEDROXYPROGESTERONE; MIFEPRISTONE; PROGESTERONE; PROGESTINS; RECEPTORS, PROGESTERONE;

EID: 64949164803     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (35)

1. Vereide AB, Ames M, Straume B, Maltau JM and Orbo A: Nuclear morphometric changes and therapy monitoring in patients with endometrial hyperplasia: a study comparing effects of intrauterine levonorgestrel and systemic medroxyprogesterone. Gynecol Oncol 91: 526-533, 2003.
2. Nilsson CG, Haukkamaa M, Vierola H and Luukkainen T: Tissue concentrations of levonorgestrel in women using a levonorgestrel- releasing IUD. Clin Endocrinol 17: 529-536, 1982.
3. Brogden RN, Goa KL and Faulds D: Mifepristone. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential. Drugs 45: 384-409, 1993.
4. Spitz IM: Progesterone antagonists and progesterone receptor modulators: an overview. Steroids 68: 981-993, 2003.
5. Chwalisz K, Brenner RM, Fuhrmann UU, Hess-Stumpp H and Elger W: Antiproliferative effects of progesterone antagonists and progesterone receptor modulators on the endometrium. Steroids 65: 741-751, 2000.
6. Murphy AA, Zhou MH, Malkapuram S, Santanam N, Parthasarathy S and Sidell N: RU486-induced growth inhibition of human endometrial cells. Fertil Steril 74: 1014-1019, 2000.
7. Prange-Kiel J, Rune GM, Wallwiener D and Kiesel L: Inhibition of proliferation and differentiation by RU 486 in human endometrial stromal and epithelial cells in vitro. Exp Clin Endocrinol Diabetes 108: 275-281, 2000.
8. Brenner RM, Slayden OD and Critchley HO: Anti-proliferative effects of progesterone antagonists in the primate endometrium: a potential role for the androgen receptor. Reproduction 124: 167-172,2002.
9. Han S and Sidell N: RU486-induced growth inhibition of human endometrial cells involves the nuclear factor-kappa B signaling pathway. J Clin Endocrinol Metab 88: 713-719, 2003.
10. Slayden OD and Brenner RM: Hormonal regulation and localization of estrogen, progestin and androgen receptors in the endometrium of nonhuman primates: effects of progesterone receptor antagonists. Arch Histol Cytol 67: 393-409, 2004.
11. Nishida M: The Ishikawa cells from birth to the present. Hum Cell 15: 104-117,2002.
12. Berthois Y, Katzenellenbogen JA and Katzenellenbogen BS: Phenol red in tissue culture media is a weak estrogen: Implications concerning the study of estrogen-responsive cells in culture. Proc Natl Acad Sci USA 83: 2496-2500, 1986.
13. Sager G, Orbo A, Jaeger R and Engstrom C: Non-genomic effects of progestins-inhibition of cell growth and increased intracellular levels of cyclic nucleotides. J Steroid Biochem Mol Biol 84: 1-8, 2003.
14. Chou TC: Derivation and properties of Michaelis-Menten type and Hill type equations for reference ligands. J Theor Biol 39: 253-276,1976.
15. Klijn JG, Setyono-Han B and Foekens JA: Progesterone antagonists and progesterone receptor modulators in the treatment of breast cancer. Steroids 65: 825-830, 2000.
16. Holinka CF, Hata H, Kuramoto H and Gurpide E: Responses to estradiol in a human endometrial adenocarcinoma cell line (Ishikawa). J Steroid Biochem 24: 85-89, 1986.
17. Schrader WT and O'Malley BW: Progesterone-binding components of chick oviduct. IV. Characterization of purified subunits. J Biol Chem 247: 51-59, 1972.
18. Berthelsen E, Endresen P, Orbo A and Sager G: Non-genomic cell growth inhibition by progesterone. Cell cycle retardation and induction of cell death. Anticancer Res 24: 3749-3756, 2004.
19. Clarke CL and Sutherland RL: Progestin regulation of cellular proliferation. Endocr Rev 11: 266-301, 1990.
20. Lange CA, Richer JK, Shen T and Horwitz KB: Convergence of progesterone and epidermal growth factor signaling in breast cancer. Potentiation of mitogen-activated protein kinase pathways. J Biol Chem 273: 31308-31316, 1998.
21. Simoncini T and Genazzani AR: Non-genomic actions of sex teroid hormones. Eur J Endocrinol 148: 281-292, 2003.
22. Lange CA: Making sense of cross-talk between steroid hormone receptors and intracellular signaling pathways: who will have the last word? Mol Endocrinol 18: 269-278, 2004.
23. Edwards DP: Regulation of signal transduction pathways by estrogen and progesterone. Annu Rev Physiol 67: 335-376, 2005.
24. Boonyaratanakornkit V and Edwards DP: Receptor mechanisms of rapid extranuclear signalling initiated by steroid hormones. Essays Biochem 40: 105-120, 2004.
25. Paulssen RH, Moe B, Gronaas H and Orbo A: Gene expression in endometrial cancer cells (Ishikawa) after short time high dose exposure to progesterone. Steroids 73: 116-128, 2008.
26. Vereide AB, Kaino T, Sager G, Arnes M and Orbo A: Effect of levonorgestrel IUD and oral medroxyprogesterone acetate on glandular and stromal progesterone receptors (PRA and PRB), and estrogen receptors (ER-alpha and ER-beta) in human endometrial hyperplasia. Gynecol Oncol 101: 214- 223, 2006.
27. Leonhardt SA and Edwards DP: Mechanism of action of progesterone antagonists. Exp Biol Med 227: 969-980, 2002.28 Navo MA, Smith JA, Gaikwad A, Burke T, Brown J and Ramondetta LM: In vitro evaluation of the growth inhibition and apoptosis effect of mifepristone (RU486) in human Ishikawa and HEC1A endometrial cancer cell lines. Cancer Chemother Pharmacol 62: 483-489, 2008.
28. Naito M, Yusa K and Tsuruo T: Steroid hormones inhibitbinding of vinca alkaloid to multidrug resistance related P- glycoprotein. Biochem Biophys Res Commun 158: 1066-1071, 1989.
29. Yang CP, DePinho SG, Greenberger LM, Arceci RJ and Horwitz SB: Progesterone interacts with P-glycoprotein in multidrug- resistant cells and in the endometrium of gravid uterus. J Biol Chem 264; 782-788, 1989.
30. Barnes KM, Dickstein B, Cutler GB, Fojo T and Bates SE: Steroid transport, accumulation, and antagonism of P- glycoprotein in multidrug-resistant cells. Biochemistry 35: 4820- 4827,1996.
31. Gruol DJ, Zee MC, Trotter J and Bourgeois S: Reversal ofmultidrug resistance by RU 486. Cancer Res 54: 3088-3091,1994.
32. Lecureur V, Fardel O and Guillouzo A: The antiprogestatin drug RU 486 potentiates doxorubicin cytotoxicity in multidrug resistant cells through inhibition of P-glycoprotein function. FEBS Lett 355: 187-191, 1994.
33. Li DQ, Wang ZB, Bai J, Zhao J, Wang Y, Hu K and Du YH: Reversal of multidrug resistance in drug-resistant human gastric cancer cell line SGC7901/VCR by antiprogestin drug mifepristone. World J Gastroenterol 10: 1722-1725, 2004.
34. Sundkvist E, Jaeger R and Sager G: Pharmacological characterization of the ATP-dependent low Km guanosine 3́',5́'- cyclic monophosphate (cGMP) transporter in human erythrocytes. Biochem Pharmacol 63: 945-949, 2002.
35. Pay en L, Delugin L, Courtois A, Trinquart Y, Guillouzo A and Fardel O: Reversal of MRP-mediated multidrug resistance in human lung cancer cells by the antiprogestatin drug RU486. Biochem Biophys Res Commun 258: 513-518, 1999.